Regeneron’s Eylea (aflibercept) Injection Receives FDA’s Approval for Diabetic Retinopathy


  • The approval is based on P-III PANORAMA study results assessing Eylea (q8w, q16w) vs sham in 402 patients with non-proliferative diabetic retinopathy (NPDR) without diabetic macular edema (DME)
  • The P-III PANORAMA study results: improvement on DRSS score by ≥2‑step (80%,65% vs 15%); @q16w & @q8w, reduction in risk (85% & 88%); @q8w, improvement in diabetic retinopathy (80%) respectively
  • Eylea (aflibercept, q8w & q16w) injection is a VEGF inhibitor, blocking the growth of new blood vessels, reduces vascular permeability in the eye by targeting VEGF-A & PLGF and has received FDA’s approval for multiple indications including wet age-related macular degeneration and DR with DME

Click here to read full press release/ article | Ref: Regeneron | Image: WCSA WORLD